Flu Model: H1N1 influenza lung infection model – viral COPD exacerbation
Influenza virus infection in humans results in a respiratory disease that ranges in severity from sub-clinical infection to primary viral pneumonia. 40-60 % of acute exacerbations in COPD are associated with respiratory virus infection; 85 % of asthma attacks in children and 44 % in adults are precipitated by upper respiratory tract infection.
For the assessment of anti-virals there is an on-site microbiology Department who will prepare, assess the viral dose and can assess viral load in the lung tissue.
This model is also useful for assessing anti-inflammatories targeted at viral respiratory induced inflammation. We also have experience of using a steroid as a positive control.
The severity and length of the model can easily be manipulated by adjustment of the initial viral titre.
Balb/c or C57BL/6J mouse, ferret
|H1N1 influenza lung infection model
|Screening and assessment of new anti-viral and anti-inflammatory drugs for viral respiratory disease
|Daily Bodyweights and Clinical Signs, Lung Function (penH, Resistance, Compliance, FEV) Viral load, BAL differential cell counts, BAL cytokines and Pathology
Study data generated by Labcorp Huntingdon Pharmacology.